Plus, news about Kvantify:
China’s Innovent takes a stake in CAR-T partner: After bringing the BCMA CAR-T therapy Fucaso to market in China, Innovent and IASO Biotechnology are reworking their deal. IASO will buy back its rights and license to the drug, and Innovent will instead get an 18% stake in IASO. — Amber Tong
Granza Bio’s $7M seed round: The Y Combinator-backed biotech plans to use the funding for its research into a new way to deliver cancer treatments and genetic medicines, CEO Ashwin Menon Nandakumar announced on LinkedIn. Granza’s big idea centers on “attack particles” discovered at its co-founder’s lab at the University of Oxford, which are essentially glycoprotein shells carrying cytotoxic proteins that could be engineered to target various tissues. Felicis and Refactor Capital led the round. — Amber Tong
Kvantify gets €10M for life sciences work: The quantum software company will use the funds to develop applications that “address complex problems in drug discovery and beyond.” The seed round was led by Danish VC Dreamcraft, with Lundbeckfonden BioCapital and 2degrees. — Ayisha Sharma